New Metabolic Influencer on Oxytocin Release: The Ghrelin.
ghrelin
ghrelin antagonist
neuropeptide regulation
oxytocin
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
18 Feb 2019
18 Feb 2019
Historique:
received:
28
01
2019
revised:
11
02
2019
accepted:
13
02
2019
entrez:
21
2
2019
pubmed:
20
2
2019
medline:
3
1
2020
Statut:
epublish
Résumé
The hypothalamic⁻pituitary axis by secreting neuropeptides plays a key role in metabolic homeostasis. In light of the metabolic regulation, oxytocin is a potential neuropeptide for therapies against obesity and related disorders. The aim of our study is to measure ghrelin-induced oxytocin secretion in rats and to detect the changes after administration of ghrelin antagonist. Ghrelin was administrated centrally (intracerebroventricular, i.c.v., 1.0, 10.0, and 100.0 pmol) or systemically (intravenous, i.v., 1.0, and 10.0 nmol). [d-Lys³]-GHRP-6 ghrelin antagonist was injected 15 min before ghrelin injection in a dose of 10.0 pmol i.c.v. and 10.0 nmol i.v. Either i.c.v. or i.v. administration of ghrelin dose-dependently increased the plasma oxytocin concentration. Following pretreatment with the ghrelin antagonist [d-Lys³]-GHRP-6, the high plasma oxytocin level induced by ghrelin was significantly reduced. The results indicate that the release of oxytocin is influenced directly by the ghrelin system. Examination of the mechanism of ghrelin-induced oxytocin secretion is a new horizon for potential therapeutic options.
Sections du résumé
BACKGROUND
BACKGROUND
The hypothalamic⁻pituitary axis by secreting neuropeptides plays a key role in metabolic homeostasis. In light of the metabolic regulation, oxytocin is a potential neuropeptide for therapies against obesity and related disorders. The aim of our study is to measure ghrelin-induced oxytocin secretion in rats and to detect the changes after administration of ghrelin antagonist.
METHODS
METHODS
Ghrelin was administrated centrally (intracerebroventricular, i.c.v., 1.0, 10.0, and 100.0 pmol) or systemically (intravenous, i.v., 1.0, and 10.0 nmol). [d-Lys³]-GHRP-6 ghrelin antagonist was injected 15 min before ghrelin injection in a dose of 10.0 pmol i.c.v. and 10.0 nmol i.v.
RESULTS
RESULTS
Either i.c.v. or i.v. administration of ghrelin dose-dependently increased the plasma oxytocin concentration. Following pretreatment with the ghrelin antagonist [d-Lys³]-GHRP-6, the high plasma oxytocin level induced by ghrelin was significantly reduced.
CONCLUSION
CONCLUSIONS
The results indicate that the release of oxytocin is influenced directly by the ghrelin system. Examination of the mechanism of ghrelin-induced oxytocin secretion is a new horizon for potential therapeutic options.
Identifiants
pubmed: 30781678
pii: molecules24040735
doi: 10.3390/molecules24040735
pmc: PMC6413225
pii:
doi:
Substances chimiques
Ghrelin
0
Neuropeptides
0
Oligopeptides
0
Receptors, Ghrelin
0
growth hormone releasing hexapeptide
4H7N4I6X6A
Oxytocin
50-56-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Regul Pept. 2001 Apr 2;98(1-2):49-54
pubmed: 11179778
Peptides. 2003 Jun;24(6):919-23
pubmed: 12948845
Diabetes. 2003 Oct;52(10):2546-53
pubmed: 14514639
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
Regul Pept. 2005 Apr 15;127(1-3):225-31
pubmed: 15680491
Neuroreport. 2007 Mar 26;18(5):499-503
pubmed: 17496811
J Clin Endocrinol Metab. 2007 Oct;92(10):3935-40
pubmed: 17652221
Obesity (Silver Spring). 2009 May;17(5):980-4
pubmed: 19247273
J Endocrinol. 2009 Oct;203(1):175-9
pubmed: 19587265
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):557-63
pubmed: 20632971
Int J Pept. 2010;2010:null
pubmed: 20798749
PLoS One. 2011;6(9):e25565
pubmed: 21980491
Int J Biol Sci. 2012;8(1):108-17
pubmed: 22211109
Endocrinology. 2013 Feb;154(2):589-96
pubmed: 23270805
PLoS One. 2013 May 20;8(5):e61477
pubmed: 23700406
Biochim Biophys Acta. 2014 Mar;1842(3):424-30
pubmed: 23774083
Diabetes. 2013 Oct;62(10):3418-25
pubmed: 23835346
Curr Opin Pharmacol. 2013 Dec;13(6):970-6
pubmed: 24075719
Drug Discov Today Dis Mech. 2013 Jun 1;10(1-2):e63-e68
pubmed: 24159336
Curr Drug Targets. 2016;17(5):495-507
pubmed: 25981609
Diabetes. 2017 Feb;66(2):264-271
pubmed: 27554476
J Mol Neurosci. 2016 Dec;60(4):525-530
pubmed: 27752928
Nat Rev Endocrinol. 2017 Dec;13(12):700-709
pubmed: 28960210